| Number: 201201124 |
Principal Investigator: Linehan, David |
| Title: A Phase IB Study of FOLFIRINOX and PF-04136309 in Patients with Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma |
| Description: The purpose of this research study is to find the best dose of the study drug (PF-04136309) in combination with FOLFIRINOX as well as to see what the side effects of this treatment regimen are. PF-04136309 is considered investigational, which means that it has not been approved by the U.S. Food and ...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201112114 |
Principal Investigator: Wang-Gillam, Andrea |
| Title: NAPOLI 1: A Randomized, Open Label Phase 3 Study of MM-398 versus 5- Fluorouracil and Leucovorin in Patients with Metastatic Pancreatic Cancer |
| Description: The primary purpose of this study is to see if MM-398 can prolong survival in patients with metastatic pancreatic cancer, when compared to 5-FU and leucovorin....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201104229 |
Principal Investigator: Hawkins, William |
| Title: A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without HyperAcute-Pancreas (algenpantucel-L) Immunotherapy in Subjects with Surgically Resected Pancreatic Cancer |
| Description: You have been diagnosed with cancer of the pancreas. Different treatments or combinations of treatments including surgery, chemotherapy, and radiation therapy may be used to treat pancreatic cancer. Because of the potential for continued growth of your pancreatic cancer, you may wish to consider t...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201103016 |
Principal Investigator: Mullady, Daniel |
| Title: The Clinical Impact of Immediate On-site Cytopathology Evaluation during Endoscopic Ultrasound-Guided Fine Needle Aspiration of Pancreatic Mass: A Multicenter, Prospective Randomized Controlled Trial |
| ___________________________________________________________________________________________________ |
| Number: 201109243 |
Principal Investigator: Linehan, David |
| Title: 30-day readmission following pancreatectomy: a root-cause analysis |
| ___________________________________________________________________________________________________ |
| Number: 201105335 |
Principal Investigator: Strasberg, Steven |
| Title: Whipple at the Splenic Artery: A Procedure for Ductal Adenocarcinoma of the Pancreas with Extensive Involvement of the Porto-Mesenteric Axis |
| Description: The main purpose of this study is to determine whether the standard surgical procedure used to remove pancreas tumors (called a Whipple procedure) is effective and safe in removing tumors located near or on the major veins that drain the intestine and spleen and supply blood to the liver. The abbrev...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201302035 |
Principal Investigator: Hawkins, William |
| Title: Accelerometer Use to Evaluate Peri-Operative Risk of Morbidity and Mortality in Pancreas Cancer Patients Undergoing the Whipple Procedure |
| ___________________________________________________________________________________________________ |
| Number: 201210092 |
Principal Investigator: Collins, Brian |
| Title: Endoscopic Ultrasound Fine Needle Aspiration Biopsy of Serous Cystadenoma of Pancreas |
| ___________________________________________________________________________________________________ |
| Number: 201106347 |
Principal Investigator: Wang-Gillam, Andrea |
| Title: A Pilot Study of Evaluation of a Phosphorylation Signature from Pancreatic Cancer Tumors |
| Description: The main purpose of this study is to see if we can use blood samples and tissue samples from a fine needle aspiration of pancreas tumors to detect proteins that are crucial for pancreatic cancer development. The study will also determine the impact of those proteins on patients with pancreatic canc...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201103202 |
Principal Investigator: Wang-Gillam, Andrea |
| Title: Construction of Pancreatic Cancer Tissue and Stroma Array |
| ___________________________________________________________________________________________________ |
| Number: 201212015 |
Principal Investigator: Hawkins, William |
| Title: Frozen Section Neck Margin in Pancreatic Adenocarcinoma |
| ___________________________________________________________________________________________________ |
| Number: 201108327 |
Principal Investigator: Wang-Gillam, Andrea |
| Title: Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies |
| Description: The purpose of this study is to determine the maximum tolerated dose and side effects of the combination of two drugs, temsirolimus and erlotinib, used to treat solid tumor cancers. Temsirolimus is approved by the Food and Drug Administration (FDA) for treatment of renal cancer and is considered inv...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201107068 |
Principal Investigator: Lockhart, A. Craig |
| Title: Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients with Varying Degrees of Hepatic Impairment |
| Description: The purpose of this study is to determine if Cabazitaxel is a safe treatment for patients with advanced cancers of different types who also have different levels of liver dysfunction. The highest safe dose of cabazitaxel (the maximum tolerated dose, or MTD) that can be given to patients with your le...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201102468 |
Principal Investigator: Lockhart, A. Craig |
| Title: An Open-Label Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 When Administered as a Single Agent in Patients With
Advanced or Metastatic Solid Tumors |
| Description: There are two parts to this research study. The purpose of Part 1 is to find out the highest safe dose of the investigational drug CEP-9722. “Investigational” means that the study drug has not been approved by the United States Food & Drug Administration (F.D.A). Part 2 of the study is to find out m...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201102462 |
Principal Investigator: Lockhart, A. Craig |
| Title: A Phase 1b, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Daily Oral Doses of ZSTK474 in Subjects with Advanced Solid Malignancies |
| Description: The main purpose of this study is to find out if the drug ZSTK474 is safe in people who have advanced cancers.
ZSTK474 is an investigational (experimental) drug. This means it has not been approved by the Food and Drug Administration (FDA). It is not currently on the market in any country. This stu...MORE |
| ___________________________________________________________________________________________________ |